Citadel Group (ASX:CGL) extends Auslab agreement

13DecDecember 13, 2019

Citadel Group (ASX:CGL) extends Auslab agreement

The Citadel Group (ASX:CGL) has signed an extension for Auslab to continue to operate for Queensland Health through to 2029.

AUSLAB has specialised functionality for supporting multiple pathology forensic laboratories.

Back in January 2018, Citadel notified the market that Queensland Health had intended to adopt a competing laboratory information system (LIS) in place of Citadel’s Auslab™ system.

Their decision to extend means Citadel will also deliver an update to Auslab™ Evolution, giving Queensland Health access to Citadel’s latest and most capable LIS software.

Shares in Citadel Group (ASX:CGL) are trading 3.87 per cent higher at $4.29.

Source: Finance News Network

29AprApril 29, 2020

Immutep (ASX:IMM) completes $12 million placement

29 Apr 2020 - Biotech company Immutep (ASX:IMM) has today successfully completed a $12 million placement to professional, institutional and sophisticated investors.

30JunJune 30, 2023

Stocks of the Hour: Blue Star Helium, Magnis Energy Technologies, Downer EDI

30 Jun 2023 - A snapshot of the stocks on the move, featuring Stocks of the Hour: Blue Star Helium, Magnis Energy Technologies and Downer EDI.

30AprApril 30, 2020

Qube Holdings (ASX:QUB) to raise $500 million

30 Apr 2020 - Qube Holdings (ASX:QUB) will raise $500 million to strengthen its balance sheet.

27DecDecember 27, 2019

Alcidion Group (ASX:ALC) signs contract for medications management solution

27 Dec 2019 - Alcidion Group (ASX:ALC) has reached an agreeement with Dartford and Gravesham NHS Trust, UK, to implement the OPENeP Electronic Prescribing and Medications Administration (ePMA) system produced by Better.

30SepSeptember 30, 2020

Recce Pharmaceuticals (ASX:RCE) in an agreement with Murdoch Childrens Institute

30 Sep 2020 - Recce Pharmaceuticals (ASX:RCE) has entered into an agreement with the Murdoch Children’s Research Institute to conduct pre-clinical studies assessing the potential of RECCE 435 (R435) for the treatment of Helicobacter pylori infections.